M. A. Flynn

发表

Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelin

A. Doherty, J. Dunbar, M. Reily, 1995 .

Endothelin antagonists: The rational design of combined and ETB receptor subtype selective antagonists

A. Doherty, W. L. Cody, E. Reynolds, 1994 .

Endothelin B receptors on human endothelial and smooth-muscle cells show equivalent binding pharmacology.

E. Reynolds, M. Flynn, K. Welch, 1998, Journal of cardiovascular pharmacology.

1-benzyl-3-thioaryl-2-carboxyindoles as potent non-peptide endothelin antagonists

A. Doherty, J. Edmunds, M. Flynn, 1996 .

1,3-DIARYL-2-CARBOXYINDOLES AS POTENT NON-PEPTIDE ENDOTHELIN ANTAGONISTS

A. Doherty, J. Edmunds, M. Flynn, 1996 .

Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors

A. Doherty, W. L. Cody, E. Reynolds, 1995 .

Structure-activity and modeling studies of tryptophan-modified peptidyl antagonists of endothelin

A. Doherty, J. Dunbar, T. Sawyer, 1994 .

Structure-activity relationships in the C-terminus of endothelin-1 (ET-1): The discovery of potent antagonists

J. Topliss, A. Doherty, W. L. Cody, 1993 .

Endothelin and PDGF enhance arachidonic acid release and DNA synthesis in vascular smooth muscle cells.

C. Irons, E. Reynolds, M. Flynn, 1996, The American journal of physiology.

Facile entry to the tetracyclic 5-7-6-3 tigliane ring system.

S. Reisman, T. Ovaska, M. Flynn, 2001, Organic letters.

In vitro Characterization of Oritavancin Clearance from Human Blood by Low-Flux, High-Flux, and Continuous Renal Replacement Therapy Dialyzers

Atul Kumar, H. Mann, T. Parr, 2011, International Journal of Artificial Organs.

In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.

A. Doherty, W. L. Cody, E. Reynolds, 1993, Journal of cardiovascular pharmacology.

Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.

J. Keiser, R. Schroeder, D. Taylor, 1995, The Journal of pharmacology and experimental therapeutics.

P066 GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: FIRST-IN-HUMAN, MUTLIPLE-DOSE STUDY IN HEALTHY SUBJECTS WITH GUT BIOPSIES

G. Opiteck, K. Peters, A. Olson, 2020, Gastroenterology.

P051 Phase 1a Safety and Pharmacokinetic Effects of GB004, a Novel Prolyl Hydroxylase Inhibitor and Potential Therapy for Inflammatory Bowel Disease

K. Peters, B. Levesque, A. Buch, 2019 .

Pharmacological differences between rat and human endothelin B receptors.

A. Doherty, B. Steinbaugh, W. L. Cody, 1995, Biochemical and biophysical research communications.

Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-[16–21, D-His16]

A. Doherty, J. Dunbar, W. L. Cody, 1993 .

Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.

A. Doherty, J. Keiser, H. Hallak, 1997, Journal of medicinal chemistry.

Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs.

K. Gallagher, P. Juneau, H. Hallak, 1996, Journal of Pharmacology and Experimental Therapeutics.

Butenolide endothelin antagonists with improved aqueous solubility.

J W Bryant, A. Doherty, J. Keiser, 1999, Journal of medicinal chemistry.

ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction.

J. Keiser, E. Reynolds, S. Haleen, 1993, Biochemical and biophysical research communications.